CD200 and melanoma: Thus, the production of CCL24 and CCL8, and the reduction of CXCL3, CXCL2, and CCL3 in TAMCs, explain why mice lacking intact CD200/CD200R signaling more potently rejected neuroblastoma and melanoma tumors relative to wild-type conditions [65].